SOM Biotech

SOM Biotech presenting plans for the SOM3355 pivotal study in Huntington's disease: https://lnkd.in/e_DRJhZB #HDSA2026 #SOM3355 #Huntingtonsdisease

A huge thank you to Huntington's Disease Society of America (HDSA) for the wonderful annual convention held in Phoenix on June 25-27, 2026. It was truly engaging for the entire Huntington's community. We are proud to support and participate in these vital moments of dialogue and connection. #HDSA2026

The innovative mechanism of action of SOM3355 is now published.   The paper provides the scientific rationale and translational relevance underlying the clinical safety and efficacy profile observed in two clinical trials in Huntington's disease.   DOI: https://lnkd.in/eJSvJXZV

On Huntington’s Disease Awareness Day, we are pleased to announce that SOM Biotech will be participating in the 2026 Huntington’s Disease Society of America 41st Annual Convention in Phoenix this June. Our CEO, Silvia Panigone, will present future plans for SOM3355 during the Clinical Trials Showcase. 📍 HDSA Convention, Phoenix, Arizona 📅 Saturday, June 27, 12:30 PM We look forward to being part of this important moment for patients, families, caregivers, clinicians, and researchers across the HD community. #HDAwarenessMonth #HuntingtonsDisease

Following Huntington’s Disease Gratitude Day, and as we approach Huntington’s Disease Awareness Month, we want to celebrate how strong and united this community is. At SOM Biotech, we stand with patients, caregivers, and families, cherishing their partnership alongside researchers and healthcare professionals — a living ecosystem we are in constant dialogue with, at the center of our efforts to design therapies that help manage everyday life, support autonomy, and address the full spectrum of HD symptoms across all stages of the disease.

As we head into #JPM, we’re pleased to announce the launch of the new SOM Biotech website. The updated site reflects who we are today: a late-stage clinical development company with a Phase 3–ready asset, pioneering AI-driven drug discovery, and a continued focus on developing treatments for rare and underserved CNS disorders. Ahead of a busy week of conversations in San Francisco, the new site provides a clearer view of our products, science, and commitment to patients and families. We invite you to explore the new website and connect with us during JPM.

The recorded webinar on Huntington’s Disease is available on SOM Website https://lnkd.in/eYhCnMDe

SOM will present at LIRH Annual Event

SOM Biotech secures clear registrational path for SOM3355 in Huntington’s disease after FDA End-of-Phase 2 Meeting